Top Neurology Podcasts of 2024 Highlight Breakthroughs in MS, Alzheimer's, and ALS Research
The neurological research and clinical community demonstrated strong engagement with key therapeutic developments and diagnostic advances through NeurologyLive®'s Mind Moments® podcast series in 2024. The most-listened episodes reflected pivotal moments in neurological medicine, from diagnostic criteria updates to breakthrough therapeutic approaches.
Major Updates to MS Diagnostic Criteria
The year's most popular episode featured Dr. Daniel Ontaneda from Cleveland Clinic's Mellen Center for Multiple Sclerosis, who detailed significant revisions to the McDonald criteria for MS diagnosis. The updated criteria, presented at the 40th ECTRIMS Congress, introduced important modifications to improve diagnostic accuracy and early disease identification. Notable changes included new approaches to pre-MS diagnosis and the incorporation of advanced biomarkers such as central vein sign, paramagnetic rim lesions, and optical coherence tomography (OCT).
Evolving Landscape of Alzheimer's Treatment
Two highly-accessed episodes focused on Alzheimer's disease developments. Ian Kremer, executive director of LEAD coalition, provided crucial insights into lessons learned from aducanumab's market withdrawal and the potential impact of newer treatments like lecanemab and donanemab. In a separate episode, Dr. Sharon Cohen discussed promising data from the phase 1 study of mivelsiran, an innovative RNA interference therapeutic targeting amyloid precursor protein, representing a potential new direction in Alzheimer's treatment approaches.
Advances in ALS Therapeutics
The podcast series captured significant developments in ALS treatment through discussions with Amylyx Pharmaceuticals' leadership. Cofounders Justin Klee and Josh Cohen shared insights from the pivotal phase 3 PHOENIX trial of AMX0035 (Relyvrio), addressing both the challenges faced and future directions for ALS therapeutic development.
Novel Approaches in Neuro-Oncology
Dr. Katherine Peters from Duke University's Preston Robert Tisch Brain Tumor Center presented new findings from the phase 3 INDIGO trial, examining vorasidenib's impact on patients with mutant IDH1/2 diffuse gliomas. The analysis revealed important data on neurocognition and seizure control, adding to the understanding of targeted therapies in neuro-oncology.
The podcast series, releasing new episodes biweekly, continues to serve as a vital platform for disseminating cutting-edge neurological research and clinical insights to healthcare professionals. Each episode combines expert commentary with detailed analysis of trial results and therapeutic implications, maintaining a balance between scientific rigor and practical clinical application.